All In Biotech

Drug Trial Radar · NCT00345501

Iloprost for Prevention of Contrast-Mediated Nephropathy in High-Risk Patients Undergoing Coronary Angiography and/or Intervention

Iloprost for Prevention of Contrast-Mediated Nephropathy in High-Risk Patients With Preexisting Renal Dysfunction Undergoing a Coronary Procedure

Last checked: Nov 20, 2026Latest source record: Aug 24, 2007 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 208 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

208

Actual

Start

Nov 2005

Primary completion

Not stated

Study completion Jul 2007

Sponsor

Lead sponsor
Onassis Cardiac Surgery CentreAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 28, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, from 18 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The prevention of contrast-mediated nephropathy (CMN), which accounts for considerable morbidity and mortality, remains a vexing problem. Contrast induced renal vasoconstriction is believed to play a pivotal role in the CMN mechanism. The aim of this study is to examine the efficacy of the prostacyclin analogue iloprost (dose 1ng/kg/min) in preventing CMN in high-risk patients undergoing a coronary procedure.

Conditions

  • Renal Insufficiency, Chronic
  • Coronary Angiography
  • Angioplasty, Transluminal, Percutaneous Coronary

Interventions

  • IloprostDrug

    Iloprost 1ng/kg/min IV starting 1 hour before the procedure and continuing for 4 hours after its end

  • PlaceboDrug

    Placebo IV (Normal saline) starting 1 hour before the procedure and continuing for 4 hours after its end

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. CMN is defined as an absolute increase of serum creatinine concentration of at least 0.5 mg/dlTime frame: 2-5 days after the procedure
  2. or CMN is defined as a relative rise of at least 25% from baseline on the follow-upTime frame: blood sample drawn at 2-5 days after the procedure

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Onassis Cardiac Surgery Centre

    Athens, Greece

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.